GFCC Life Science (CEO Kang Hee-chul) announced on the 3rd that it has signed a strategic business agreement (MOU) with domestic medical device distribution company Person Healthcare (CEO Kim Dong-jin) and will be entering the new medical aesthetics business in earnest. The company plans to officially launch the hyaluronic acid (HA)-based filler 'GFCCELL Luxe Filler' in Korea on the 6th.
GFC Cell Luxe Filler is an HA filler that achieves stable volume retention based on high viscoelasticity, cohesiveness, and a uniform cross-linking structure. It is available in three types: SHAPE for deep wrinkle improvement, DEEP for soft tissue wrinkle improvement and volume restoration, and FINE for fine wrinkle improvement. The product line is differentiated based on the treatment purpose.
With this filler launch, GFC Life Sciences is moving beyond its existing business structure, which primarily focuses on exosome-based skin boosters, to build a full-line portfolio encompassing both medical and aesthetic products. The company's strategy is to diversify its sales structure and strengthen its mid- to long-term growth momentum by expanding its product line.
Through this MOU, the two companies will jointly promote the sales and distribution of GFC Cell Luxe Filler to hospitals and clinics in Korea. Person Healthcare will leverage its nationwide distribution network and medical device sales experience to spearhead the domestic filler market, while GFC Life Sciences will use this to secure a stable distribution base and achieve early sales visibility.
In overseas markets, GFC Life Science will gradually expand the global distribution of its filler products by leveraging its network of overseas dealers and agents in 32 countries. Person Healthcare will support this global expansion by identifying overseas export channels and providing market information.
In addition to the filler business, the two companies will collaborate on expanding global markets for medical devices for which GFC Life Science has secured export approval. This collaboration will include topical hydrogel wound dressings and non-sterile medical gels, and they plan to jointly pursue export strategies tailored to the specific market characteristics of each country.
Kang Hee-chul, CEO of GFC Life Science, said, “With the launch of GFC Cell Luxe Filler, we have begun to launch our new filler business in earnest,” and “Through our collaboration with Person Healthcare, we plan to secure a domestic distribution base early on and gradually expand sales starting from Korea to the global market.”
- See more related articles
You must be logged in to post a comment.